After Leerink Partners and H.C. Wainwright gave AVEO Pharma (NASDAQ: AVEO) a Buy rating last month, the company received another Buy, this time from Stifel Nicolaus. Analyst Stephen Willey maintained a Buy rating on AVEO Pharma yesterday and set a price target of $14.00. The company's shares closed last Tuesday at $4.98. According to TipRanks.com, Willey is a 5-star analyst with an average return of 17.2% and a 46.7% success rate. Willey covers the Healthcare sector, focusing on stocks such as Inovio Pharmaceuticals, AbCellera Biologics, and Nurix Therapeutics. Currently, the analyst consensus on AVEO Pharma is a Strong Buy with an average price target of $15.75, implying a 220.
https://www.tipranks.com/news/blurbs/aveo-pharma-aveo-received-its-third-buy-in-a-row?utm_source=advfn.com&utm_medium=referral
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more AVEO Pharmaceuticals Charts.
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more AVEO Pharmaceuticals Charts.